New Committee on Rheumatologic Care (CORC) Chair Chris Phillips, MD, talks about his past work with the ACR, his experience as a private practice rheumatologist and his plans to lead CORC in addressing practitioner pain points and supporting the business side of rheumatology practice.
An array of new and expanded indications of therapeutics for rheumatic disease last year relied on pharmacokinetic modeling for intravenous dosing and efficacy extrapolation for pediatric populations.
A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.
In late October, the FDA approved the first biosimilar to ustekinumab to treat patients with psoriasis, psoriatic arthritis and other conditions. Ustekinumab-auub is expected to be available in the U.S. by 2025.
Last month, the ACR’s delegation to the AMA House of Delegates discussed and advanced resolutions to address specialty workforce shortages, payment reform and access to care.
The Department of Health & Human Services and Drug Enforcement Administration have extended through Dec. 31, 2024, exceptions that allow providers to prescribe controlled medications via telemedicine appointments without conducting an in-person evaluation.
Speakers discussed common payer practices and policies that rheumatologists must navigate to secure and maintain appropriate care for their patients, including pharmacy benefit managers and prior authorization.
Liana Fraenkel, MD, MPH, credits much of her own career success to support from the Foundation, and she is eager to advance its mission during her presidency.
Rheumatologists in community practices don’t have to abandon their research interests. The Rheumatologist recently interviewed three community practice rheumatologists from around the U.S. to find out their approaches to patient management, staffing and other areas of the practice. Here, they discuss their approach to incorporating research into their practice. At New England Rheumatology & Osteoporosis,…
In 1937, the Turkish physician Hulusi Behçet described a number of patients with relapsing aphthous ulcers in the mouth and over the genitalia, as well as hypopyon iritis. Since that time, the eponymous condition, known as Behçet’s disease, has been recognized as a multisystem vasculitis that can present with myriad other signs and symptoms. Although…